Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside
Stock Rally on Novel Cancer Data Intensity Therapeutics (NASDAQ: INTS) has been one of the market’s biggest movers. On Oct. 30, 2025 its stock was around $0.27 per share investing.com – an 84% drop YTD but up nearly 200% intraday on the news of its Lancet-published trial tipranks.com. Trading volume exploded: ~279 million shares traded on Oct. 30 vs. an average of ~5 M per day tipranks.com. The rally was sparked by the Phase 1/2 study announcement that Intensity’s lead drug, INT230‑6, showed striking tumor control in advanced cancer. The study covered 64 patients across 20+ tumor types – most had failed multiple therapies.
